Persons with genetic conditions cannot be asked by their employers, or any other agency, to disclose that information.
- Amicus Remains Hopeful about AT-GAA Despite Mixed Results from Phase 3 Study
- Cheryl Wong Po Foo
- Spark Therapeutics Has Begun a Phase 1/2 Gene Therapy Study for Late-Onset Pompe Disease
- Amicus Therapeutics Has Begun the FDA Submission for Their Pompe Drug, AT-GAA
- New Review Article Highlights Latest Developments in Pompe Disease Research